While some NENs such as melanoma and non-small cell lung cancer (NSCLC) showed promising results regarding PD-1/PD-L1 expression and ICIs, the management recommendations for certain cancers, such as merkel cell carcinoma (MCC), requires additional clinical trial data to better inform IO management (55). This evidence concerns the gene CD274 and melanoma.